SAN ANTONIO, Texas – BlueRiver Acquisition Corp. (NYSE American: BLUA), a company specializing in surgical and medical instruments, has been delisted from the NYSE American exchange following a series of regulatory challenges.
The NYSE American LLC announced the suspension of trading in BlueRiver's Class A ordinary shares and units on Monday, July 15, 2024, leading to the formal delisting of the company's securities.
The exchange's staff made the decision to delist the securities, which also include redeemable warrants, after the company withdrew its appeal against an earlier delisting determination announced on February 2, 2024. BlueRiver's redeemable warrants had already been suspended from trading on July 3 due to abnormally low selling prices.
The delisting process was completed when the NYSE American filed a Form 25 with the Securities and Exchange Commission, effectively removing BlueRiver's securities from the exchange. In response to the delisting, BlueRiver may seek to have its securities quoted on the OTCQX Marketplace, a trading platform for over-the-counter stocks. Still, the company has cautioned that there can be no assurance regarding the future trading of its securities on this or any other market.
The delisting represents a significant regulatory hurdle for BlueRiver, potentially affecting the company's stock liquidity and investor relations. The company has not provided further details on its plans following the delisting, nor has it commented on the potential impact on its operations or financial performance.
This news is based on a recent SEC filing by BlueRiver Acquisition Corp. and contains forward-looking statements that involve risks and uncertainties. The company has emphasized that these statements are not guarantees of future performance and that actual results may differ materially from those projected in the forward-looking statements. BlueRiver has stated that it does not intend to update these forward-looking statements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.